A: Digital pathology is applicable across virtually all surgical pathology specialties, though adoption rates vary by specialty. Lumea currently serves three primary markets: urology (particularly prostate cancer diagnostics, where we support over 40% of the U.S. outpatient market), dermatopathology (where high case volumes make digital workflows and AI tools especially valuable), and gastroenterology (where GI Alliance, the nation’s largest GI network, recently adopted Lumea’s platform). Other specialties with strong digital pathology adoption include neuropathology, breast pathology, hematopathology, and cytopathology. Across all specialties, the clinical use cases are similar: remote diagnosis, teleconsultation, AI-assisted analysis, tumor boards, and research. Lumea’s specialty-specific approach means the platform is configured for the clinical nuances of your workflow, not just generically digitized.

A: Not with the right implementation, and Lumea is specifically designed to prevent the slowdowns that have plagued other digital pathology deployments. The most common bottleneck in digital pathology is the gap between scanning and diagnosis: slides get scanned but the viewer, LIS, and AI tools are all in separate systems, creating more toggling and more friction than the microscope it replaced. Lumea solves this with a single-screen diagnostic workspace where the viewer, case management, AI results, and report generation are all integrated. Pathologists who have made the transition with Lumea consistently report improved efficiency, not slower workflows. Dr. Adam Cole of TruCore Pathology describes Lumea as “perfectly positioned to allow pathologists to enter into the digital pathology space,” bridging the gap rather than adding to it. Read more about digital pathology speed and efficiency at lumeadigital.com/digital-pathology-efficiency.

A: Yes. Multiple peer-reviewed studies have demonstrated that diagnostic concordance between digital and glass slide pathology is equivalent, and in some applications, particularly when AI assistance is used, digital pathology has shown improved accuracy. Lumea’s platform has received FDA 510(k) clearance for primary clinical diagnosis, which requires demonstrated equivalence to traditional methods. It is worth noting that accuracy in both digital and traditional pathology depends significantly on the quality of the specimen itself. This is why Lumea’s approach starts before the scanner: our tissue-handling technology (BxBoard, BxChip, BxCamera) is designed to improve specimen integrity from the moment of biopsy, giving pathologists better material to work with regardless of the diagnostic method. Read more about digital pathology accuracy at lumeadigital.com/increase-prostate-cancer-detection/.

A: Yes, and for most labs it comes faster than expected. Labs using Lumea’s tissue-handling technology typically see return on investment within three months of implementation. Beyond that initial payback, ongoing savings accumulate across multiple areas: reduced courier and shipping costs, lower physical storage requirements for glass slides, fewer diagnostic errors and re-cuts, faster turnaround times, and the ability to scale pathologist capacity without proportional staffing increases. AI integration adds another layer of efficiency by handling high-volume, repetitive analysis tasks. Lumea customers have documented measurable improvements including a 19% increase in cancer detection rates and a 35% reduction in tissue fragmentation, both of which directly impact clinical outcomes and operational costs. For a detailed breakdown, read more about ROI in digital pathology at lumeadigital.com/digital-pathology-viable-valuable/.

A: The upfront cost of digital pathology implementation is real, but so is the financial case for doing it. Labs that have implemented Lumea’s full platform typically recover their investment within three months through efficiency gains, reduced shipping and courier costs, lower slide storage expenses, and fewer repeat procedures due to specimen quality improvements. For practices that need to start smaller, Lumea’s modular approach means you can begin with the viewer or tissue-handling technology and expand from there. The more relevant question is often not “can we afford digital pathology” but “what is the cost of not adopting it”: competitive positioning, pathologist recruitment, and the ability to offer AI-assisted diagnostics that patients and referrers increasingly expect. For a detailed cost breakdown and ROI analysis, read more at lumeadigital.com/is-digital-pathology-too-expensive/.

A: LIS integration is one of the most important, and most commonly underestimated, factors in a successful digital pathology implementation. Without deep LIS integration, digital pathology creates a parallel workflow that pathologists must toggle between, which erodes efficiency gains and drives adoption problems. Lumea approaches this differently: our BxLink platform is a digital pathology-enabled LIS that manages case intake, image routing, AI result integration, molecular test ordering, and report generation in a single workspace. For labs with existing LIS systems, Lumea’s Viewer+ also integrates with third-party LIS platforms. When evaluating any digital pathology solution, ask vendors specifically about their LIS integration depth. Whether it is a full bidirectional integration or simply a link that opens the viewer in a separate window makes an enormous operational difference.

A: Implementation timelines vary based on the scope of deployment, existing infrastructure, and whether FDA validation for primary diagnosis is required. A typical Lumea deployment, including software setup, LIS integration, staff training, and validation, runs between three and nine months from contract to go-live. Labs that start with a focused deployment (such as the viewer only, or tissue-handling technology only) can move faster. The validation requirement is often the longest phase: FDA guidance requires labs to validate their digital workflow before using it for primary diagnosis, which involves comparing digital and glass slide diagnoses across a defined case set. Lumea’s implementation team guides customers through this process and has developed streamlined validation protocols based on deployments across hundreds of labs. Request a demo to get a timeline estimate specific to your lab’s situation.

A: Yes, and Lumea was specifically designed with independent and smaller practices in mind. Many digital pathology solutions are built for large academic medical centers with dedicated informatics staff, making them impractical for independent urology groups, dermatology practices, or community hospital labs. Lumea’s modular platform lets smaller practices start with the components that address their biggest bottleneck, whether that is tissue-handling technology, the viewer, or molecular test integration, and scale from there. Our smallest customers are single-pathologist practices; our largest are nationwide networks processing hundreds of thousands of cases annually. The same platform serves both because it is built around workflow flexibility rather than a one-size-fits-all architecture. 

A: Whole slide imaging is the process of digitizing an entire glass pathology slide into a single high-resolution digital image, typically at 20x or 40x magnification, that can be viewed, navigated, and analyzed on a computer screen or tablet. A WSI scanner photographs the slide in a grid of overlapping fields and stitches them together into one seamless image that can be 1-2GB in size. Once digitized, the whole slide image can be accessed from any location, shared instantly with colleagues, analyzed by AI tools, and stored permanently in a digital archive. WSI is the foundational technology that makes digital pathology possible; it replaces the need for a physical microscope while adding capabilities the microscope never had. Lumea’s Viewer+ is FDA-cleared for primary clinical diagnosis using whole slide images and is compatible with images from all major scanner manufacturers.

A: Computational pathology refers to the use of algorithms, machine learning, and artificial intelligence to analyze digital pathology images. It goes beyond simply viewing a digitized slide; computational tools can detect mitotic figures, quantify biomarkers, grade tumors, flag regions of interest, and identify patterns invisible to the human eye. Several computational pathology AI tools are now FDA-cleared for specific applications, including prostate cancer Gleason grading and lymph node metastasis detection. Lumea’s open AI ecosystem allows labs to integrate leading computational pathology tools from partners including Paige, Primaa, Mindpeak, AIRA Matrix, and others directly into the diagnostic workspace, so AI results appear alongside the image without requiring pathologists to switch platforms. Learn more about the top AI companies for digital pathology at lumeadigital.com/top-10-ai-companies-for-digital-pathology/.

A: Lumea’s platform is designed and maintained in full compliance with HIPAA, HITECH, and all relevant U.S. patient data regulations. Modern encryption and authentication protocols secure all connections between browsers, applications, and storage systems, including remote access by pathologists working from home or satellite locations. Lumea can provide compliance documentation upfront, and our Information Security Officer is available to address any specific questions your IT or compliance team may have. One important note: your practice retains responsibility for the security of the endpoint devices used to access the platform, including workstations, laptops, and tablets. This means keeping software updated, using strong passwords, and following your organization’s device security policies. If you have specific compliance requirements, bring them to your demo conversation and we will address them directly.